Removal of Benign Odontogenic Cyst or Tumor — Lesion Diameter Up to 1.25 cm Template

Removal of benign odontogenic cyst or tumor - lesion diameter up to 1.25 cm.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Site: Site/tooth area
Lesion description: Lesion description
Size: Size
Radiographic findings: Radiographic findings

Consent: Consent/PARQ reviewed; signed/verbally obtained

Anesthesia: Anesthetic used
Carps: Carpules/amount

Surgical procedure support: Specific site/teeth, indication, and medical necessity
Operative details: Surgical access, tissue/bone removed or repositioned, closure materials
Image/specimen support: Radiographs/photos/specimen/lab as applicable

Procedure:
Incision made.
Mucoperiosteal flap elevated.
Cyst exposed.
Cyst enucleated.
Specimen submitted to pathology.
Curettage of bony cavity.
Copious irrigation.
Flap repositioned.
Sutured with: Suture material/size
Hemostasis achieved.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
Rx: Prescription or none

Pathology results to be discussed at follow-up.

NV: Next visit

Documentation requirements

D7450 is a surgical-pathology code: the chart and the pathology report together are the medico-legal record. Carriers expect imaging, an unambiguous size measurement, a procedure narrative that documents enucleation (not incidental curettage), and a pathology submission. The oral surgery chapter and AAOMS Parameters of Care both call out a specific documentation set for cyst/tumor enucleation; missing items invite denials and, more seriously, malpractice exposure if a recurrence or missed malignancy is later identified. A defensible D7450 note must contain:

• Date of service and start/stop time — surgical visits should always carry a procedure time. Cyst enucleations often qualify for medical-payor cross-coding where time supports the level of work.
• Medical and dental history reviewed — including anticoagulant therapy (warfarin, DOACs, antiplatelets), bleeding disorders, immunosuppression, anti-resorptive or antiangiogenic therapy (MRONJ risk), prior head/neck radiation, prior oral cancer or syndromic history (Gorlin syndrome / nevoid basal cell carcinoma syndrome — relevant for OKCs), tobacco and alcohol use, and any condition affecting bone healing.
• Vitals — pre-op BP and pulse; post-op vitals when extended visit, sedation, or significant anesthetic volume. Many state boards require vitals on operative visits.
• Chief complaint and history of present illness — symptomatic vs incidental finding (most small odontogenic cysts are incidental on routine imaging), how / when discovered, prior treatment attempted, prior endodontic therapy on the involved tooth (relevant for periapical / residual cyst etiology).
• Site / anatomical location — specific named site (e.g., "periapical to #19 mesial root, mandibular left posterior body"), with reference to the tooth or edentulous region, the side, and the anatomical landmark relationships (IAN canal, mental foramen, sinus floor, nasal floor, adjacent root apices).
• Lesion description — clinical and radiographic findings — clinical findings (cortical expansion, palpable swelling, drainage, paresthesia, mobility of adjacent teeth) and radiographic findings (well-defined unilocular vs multilocular radiolucency, sclerotic vs corticated border, scalloped border, association with an unerupted tooth crown [dentigerous] vs apex of a non-vital tooth [periapical] vs prior extraction site [residual], displacement vs resorption of adjacent roots, IAN canal displacement, sinus elevation, cortical perforation). Avoid conclusory language without imaging support.
• Size in millimeters in three dimensions — measured on CBCT (preferred) or on PA / panoramic with appropriate magnification correction. The greatest dimension determines the D7450 vs D7451 selection; document the measurement explicitly (e.g., "8 mm AP × 7 mm SI × 6 mm BL on CBCT axial / coronal / sagittal slices"). The 1.25 cm threshold is the most common downgrade / upgrade audit point.
• Pre-operative imaging — required — periapical and / or panoramic for nearly all cases; CBCT is the modern standard for sizing, root involvement, cortical assessment, and IAN / sinus / nasal floor relationships. Document the imaging modality, date, and the specific findings linking the image to the lesion. Bill imaging under separate codes (D0220 / D0274 / D0330 / D0364-D0368) when exposed; they are not bundled into D7450.
• Differential diagnosis / clinical impression — the working diagnosis before pathology (e.g., "periapical cyst vs apical granuloma vs residual cyst" or "dentigerous cyst vs OKC vs unicystic ameloblastoma"). The differential grounds the indication and the pathologist's interpretation.
• Consent / PARQ — signed written consent is strongly preferred for D7450. PARQ should cover the rationale (surgical removal of pathology, histopathologic confirmation of benignity, prevention of expansion / fracture / displacement of adjacent structures), alternatives (observation with serial imaging, marsupialization for very large or critically located lesions, referral to OMFS), and risks (bleeding, infection, paresthesia / dysesthesia of IAN or mental nerve for posterior mandibular cases, lingual nerve injury, oroantral or oronasal communication for maxillary cases, root injury or devitalization of adjacent teeth, jaw fracture for larger lesions in atrophic mandible, recurrence — particularly for OKCs and ameloblastic tumors — and the possibility that pathology may upgrade the diagnosis to a more aggressive lesion requiring additional surgery).
• Anesthesia — local agent and concentration, vasoconstrictor, technique (block / infiltration), carpule count. Document landmarks and negative aspirations for blocks. Note any sedation (D9230 nitrous, D9243 IV moderate sedation, D9248 non-IV moderate sedation) when used; sedation is billed separately.
• Surgical approach / flap design — full-thickness mucoperiosteal flap, sulcular vs envelope vs three-corner design with relieving incisions, extent of reflection, periosteal preservation. Photographs or a simple sketch in the chart strengthen the record for larger lesions.
• Ostectomy — bone removal as needed for access; describe the tools (high-speed handpiece with surgical bur, piezoelectric, rongeur), volume of bone removed, and confirmation that vital structures (IAN canal, mental foramen, sinus floor, nasal floor, adjacent root apices) were identified and protected.
• Enucleation technique — confirm the lesion was enucleated (cyst lining or tumor capsule removed intact when possible) rather than incidentally curetted. For OKCs and other recurrence-prone lesions, document peripheral ostectomy (~1-2 mm of surrounding bone removed) and / or adjunctive treatment (Carnoy's solution / modified Carnoy's, cryotherapy with liquid nitrogen) when used; these adjuncts are part of the standard of care for OKC management and reduce recurrence rates.
• Specimen handling and pathology submission — mandatory — the entire enucleated specimen placed in 10% neutral buffered formalin, container labeled with patient name, DOB, site, and date, with a requisition that includes patient demographics, site, clinical and radiographic findings, working differential, and treating clinician contact. Document the pathology laboratory name (e.g., regional oral and maxillofacial pathology service, hospital pathology, ProPath, Aurora Diagnostics) and the specimen tracking / accession number when available.
• Cavity management — copious irrigation with sterile saline (and / or chlorhexidine), confirmation of clean bony walls, hemostasis, and any grafting material placed (allograft, xenograft, autograft from local site, collagen plug). Bone grafting at the same site same DOS is reported separately under the appropriate grafting code (e.g., D7953 bone replacement graft for ridge preservation, D4263 bone replacement graft — first site in quadrant — for periodontal sites) only when separately indicated; many small enucleation cavities heal by secondary intention without grafting.
• Closure — flap repositioned, suture material, gauge, and pattern. Resorbable sutures (chromic gut, polyglycolic acid) are typical; document suture-removal plan if non-resorbable.
• Hemostasis — explicit confirmation. Document specific measures for patients on anticoagulants (local hemostatic agents, packing, extended pressure).
• Complications — explicit "None" or describe (excessive bleeding, IAN exposure, sinus communication, adjacent tooth injury, mandible fracture concern). Photo documentation of any complication is good practice.
• Patient tolerance and post-op vitals — tolerated well, mild discomfort managed, etc. Note post-op vitals if sedation or extended visit.
• Post-op instructions — soft diet 24-72 hours depending on size, no smoking / no straws / no vigorous rinsing for 24 hours, gentle salt-water rinses starting day 2, expected bleeding and swelling course, NSAID regimen and analgesic plan, return precautions for prolonged bleeding / increasing pain / swelling / fever / numbness persisting beyond expected anesthesia duration / signs of oroantral communication for maxillary cases.
• Prescription — analgesic (NSAID first-line, opioid only when justified) and antibiotic when clinically indicated (immunocompromise, larger cavity, contaminated field, pre-existing infection, sinus involvement). Document the rationale either way; antibiotic prophylaxis is not universal for small enucleations.
• Pathology-result follow-up plan — explicit documentation of how the result will be communicated (phone call, portal message, in-person visit), expected turnaround (5-10 business days), and the next-step decision tree depending on the result (benign odontogenic cyst confirmed: routine post-op follow-up and radiographic surveillance; OKC confirmed: extended surveillance interval and counseling on recurrence and Gorlin syndrome workup if multiple OKCs or family history; unexpected upgrade to aggressive or malignant lesion: immediate referral to OMFS / head-and-neck oncology).
• Recurrence-surveillance plan — radiographic follow-up at defined intervals appropriate to the lesion. Standard cadence: PA or panoramic at 6 months and 12 months for periapical / residual / dentigerous cysts; 5-year (and ideally longer) annual surveillance for OKCs given documented recurrence rates of 25-60% in published series. Document the cadence in the chart, not just "monitor for recurrence."
• Provider signature and assistant initials — required.

Two phrases that defuse the most common D7450 audit and malpractice questions: an explicit "lesion diameter X mm (greatest dimension) on pre-op CBCT, confirmed on enucleated specimen" line, and an explicit "specimen sent to [named pathology lab] on [date]; results to be reviewed with patient at follow-up" line. Together they document the size threshold and the closed-loop pathology responsibility that benign-tumor-removal procedures carry.

Common denial reasons

D7450 has its own denial pattern, distinct from extraction or biopsy codes. The most frequent reasons it is denied, downgraded, or recouped:

• No pre-op imaging submitted. The single most common cause. Carriers require radiographic evidence of the lesion's size, location, and odontogenic origin. Submitting D7450 without a PA, panoramic, or CBCT triggers an automatic request-for-information (RFI) at best, denial at worst.
• Lesion size not documented or inconsistent across the chart. When the operative note, the pathology report, and the imaging measurement disagree on the greatest dimension, carriers default to the lower-paying interpretation. Document the measurement explicitly on the CBCT (axial / coronal / sagittal) and confirm against the pathology measurement.
• Lesion exceeds 1.25 cm — recode to D7451. A lesion measured at >1.25 cm in greatest dimension should be reported as D7451. Submitting D7450 for an oversized lesion is a coding error and a recoupment trigger.
• Lesion is non-odontogenic — recode to D7460 / D7461. Nasopalatine duct cysts, simple bone cysts, aneurysmal bone cysts, central giant cell granulomas, and fibro-osseous lesions are not odontogenic. Pathology report origin determines the code; pre-operative working diagnosis does not.
• Pathology specimen never sent / not documented. D7450 implies a specimen is submitted to a pathology laboratory. A chart that records lesion enucleation but no pathology submission supports denial as inappropriate code selection or recoupment after audit. Pathology submission is mandatory.
• Pathology shows malignancy — recode to D7440 / D7441. When the final histopathology indicates malignancy, the appropriate code is D7440 (malignant tumor ≤1.25 cm) or D7441 (>1.25 cm), not D7450. Carriers may either reprocess the original claim under the malignant code (typically higher reimbursement) or deny D7450 and request resubmission under the correct code.
• Same-DOS billing with same-tooth apicoectomy (D3410 / D3421 / D3425 / D3426 / D3427). Most carriers bundle periapical cyst removal into the apicoectomy code on the same tooth. A separate D7450 on the same tooth same DOS is denied unless the lesion is clearly distinct from the periapical pathology of the apicoectomy.
• Same-DOS billing with same-site extraction (D7140 / D7210 / D7220-D7241). When the cyst is small, periapical to the extracted tooth, and removed as part of socket curettage, carriers commonly bundle the work into the extraction. Separate D7450 requires documentation of size threshold, discrete lesion appearance on imaging, and surgical approach beyond the extraction socket.
• Procedure reads as routine extraction with apical granuloma curettage. Granulomas are not cysts, do not require formal enucleation, and are not separately reportable as D7450. Distinguish granuloma (inflammatory, no epithelial lining, bundled with extraction) from cyst (epithelial-lined, requires formal enucleation, separately reportable when criteria are met).
• No clinical / radiographic differential documented. The chart should explain why the lesion was identified as a benign odontogenic cyst or tumor on pre-op imaging. Absent a differential, reviewers question medical necessity and code selection.
• Specimen-handling errors. Formalin not used (or wrong fixative for special studies), unlabeled container, missing requisition, wrong site labeled. The pathologist's report comes back as "specimen non-diagnostic" or "tissue insufficient for evaluation," which both undermines the claim and creates malpractice exposure.
• Cosmetic framing in the chart. Language suggesting the indication is appearance rather than removal of pathology supports a denial as cosmetic / non-covered. Frame the indication as removal of biopsy-confirmed (or imaging-suggestive) pathology with histopathologic confirmation.
• PARQ silent on recurrence and possible upgraded diagnosis. OKCs and ameloblastic lesions have well-documented recurrence rates; consent that does not address recurrence, surveillance, and the possibility of pathology upgrading to a more aggressive lesion supports a malpractice claim if recurrence or malignancy is later identified.
• No recurrence-surveillance plan documented. Increasingly flagged as a missing closing element. Standard cadence (6 mo, 12 mo, then annual to 5 years for OKCs) should be in the chart, not just "monitor."
• Predetermination not obtained where required. Several Delta member companies, most Medicaid MCOs, and a number of commercial plans require pre-treatment estimate for D7450 / D7451. Submitting without a predetermination on a plan that requires one results in automatic denial pending RFI.
• Practice-level audit triggers. Elevated D7450 frequency, D7450 bundled with same-tooth extractions or apicoectomies without supporting narratives, biopsy-to-enucleation ratios that read as upcoded extractions, and absent pathology-lab claims all draw chart audits. Several state OIG dental fraud reports cite cyst-enucleation patterns.

Related templates